Triplet regimen yields promising response in advanced-phase chronic myeloid leukemia

Estimated reading time: 1 minutes

• About The Author

According to new research, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML) — including both accelerated or myeloid blast phases of the disease — or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib.

About The Author

See author's posts

Trending

Android malware steals payment card data using previously unseen technique